AngioDynamics, Inc. filings document regulatory disclosures for a Nasdaq-listed medical technology company focused on vascular disease, thrombectomy, oncology and surgical device markets. Recent Form 8-K reports furnish quarterly and annual financial results, Regulation FD investor presentation materials, and forward-looking statement language tied to product strategy, competitive position, cash flows and operating plans.
The filing record also covers governance and material-event disclosures, including annual meeting voting results, director elections, auditor ratification, advisory executive-compensation votes, executive transition and retirement arrangements, and patent-enforcement litigation involving the company’s thrombectomy intellectual property and self-expanding funnel technology. Proxy materials provide compensation tables, board matters and shareholder-vote mechanics.
AngioDynamics, Inc. Schedule 13G/A: Point72 reports beneficial ownership of 3,181,829 shares of common stock, representing 7.7% of the class as of March 31, 2026. The shares are held by Point72 Associates; voting and dispositive power are reported as shared. Point72 Asset Management and Point72 Capital Advisors Inc. state they own no shares directly; Steven A. Cohen is reported to control the filing entities.
AngioDynamics reported higher sales but remained unprofitable for the quarter ended February 28, 2026. Revenue rose 8.9% to $78.4 million, driven by 19.0% growth in Med Tech and 1.2% growth in Med Device.
Quarterly gross margin slipped to 52.9% as tariffs, inflation and Med Device mix offset volume and outsourcing benefits. Net loss widened to $8.1 million (loss per share $0.19) from $4.4 million, largely reflecting higher restructuring and CEO transition costs.
For the nine months, revenue increased to $233.6 million (up 10.0%) and net loss improved to $25.3 million (loss per share $0.61) from $27.9 million. The company ended the period with $37.8 million in cash, no debt and access to a $25.0 million revolving credit facility while continuing a multi‑year manufacturing footprint restructuring and ongoing payments under a patent settlement with BD.
AngioDynamics reported fiscal Q3 2026 results showing solid Med Tech–led growth but continued GAAP losses. Net sales were $78.4 million, up 8.9% year over year, with Med Tech revenue of $37.3 million growing 19.0% and Med Device revenue of $41.1 million up 1.1%.
Gross margin was 52.9%, down 110 basis points, reflecting tariffs, inflation and manufacturing transition costs. The company posted a GAAP net loss of $8.1 million, or ($0.19) per share, and a pro forma adjusted net loss of $3.0 million, or ($0.07) per share, while pro forma adjusted EBITDA improved to $1.8 million.
AngioDynamics ended the quarter with $37.8 million in cash and no debt. It raised full-year 2026 guidance, now expecting net sales of $313.5–$315.5 million, Med Tech growth of 15–17%, adjusted EBITDA of $10.0–$12.0 million, and adjusted EPS between ($0.30) and ($0.23).
AngioDynamics Inc amendment shows The Vanguard Group reports 0 shares of Common Stock beneficially owned, representing 0% of the class as stated in the filing. The amendment explains an internal realignment effective January 12, 2026, leading Vanguard and certain subsidiaries to report holdings separately.
AngioDynamics, Inc. received an amended Schedule 13G/A from Divisadero Street Capital Management and related entities, along with William Zolezzi, reporting a very small passive position in its common stock. The group reports beneficial ownership of 4,576 shares, representing 0.01% of AngioDynamics’ outstanding common stock.
The filing shows no sole voting or dispositive power over the shares; all reported power is shared among the reporting persons. All of the securities are directly owned by advisory clients of Divisadero Street Capital Management, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.
The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and that overall ownership remains at or below 5% of the class.
Systematic Financial Management filed a Schedule 13G reporting a passive ownership stake in AngioDynamics Inc. common stock. The firm beneficially owns 2,508,295 shares, representing 6.05% of the outstanding common stock, with sole voting power over 1,478,345 shares and sole dispositive power over all 2,508,295 shares.
The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AngioDynamics. The reported holdings relate to AngioDynamics common stock with CUSIP 03475V101.
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
AngioDynamics outlined a planned leadership transition and retention program for senior executives. President and CEO James C. Clemmer signed a Transition and Retirement Agreement under which he will continue as CEO until a successor is appointed or until November 30, 2026, with possible month‑to‑month extensions by mutual agreement. His existing stock options and service-based restricted stock units will continue to vest until his service as a consultant or director ends, after which they immediately vest, while performance-based restricted stock units may still vest according to their original terms. The board also approved retention agreements for the executive leadership team: key named executive officers are eligible for cash retention awards equal to 150% of base salary and others for 50% of base salary, if they remain employed until the earlier of six months after the new CEO starts or June 1, 2027.
AngioDynamics, Inc. filed a current report after its President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company has made the conference presentation slides available as Exhibit 99.1, furnishing them for informational purposes.
The report clarifies that these slides are furnished rather than filed, meaning they are not subject to certain liability provisions and are not automatically incorporated into other securities filings. It also includes a detailed caution about forward-looking statements, noting that expectations about strategy, products, financial position and growth are subject to numerous risks, including regulatory actions, economic conditions, competition, supply chain challenges and factors described in prior AngioDynamics SEC reports.